Restrepo M I, Najvar L K, Fothergill A W, Graybill J R
The University of Texas Health Science Center at San Antonio, USA.
Med Mycol. 1998 Jun;36(3):181-4.
BMS 181184 (BMS), an analogue of pradimicin, was administered intravenously to neutropenic mice infected with either a fluconazole-susceptible or a fluconazole-resistant clinical isolate of Candida tropicalis. BMS prolonged survival at doses >3 mg kg -1 day-1, and at higher doses reduced tissue counts in mice. BMS was less potent mg for mg than amphotericin B. Combined BMS and amphotericin B were no more effective than either of the individual drugs.
BMS 181184（BMS）是 pradimicin 的类似物，通过静脉注射给予感染热带念珠菌氟康唑敏感或氟康唑耐药临床分离株的中性粒细胞减少小鼠。BMS 在剂量>3mg kg-1 天-1 时可延长生存期，且在更高剂量时可减少小鼠组织中的菌量。BMS 每毫克的效力低于两性霉素 B。BMS 与两性霉素 B 联合使用并不比单独使用任何一种药物更有效。
